Astrana Health's earnings call showcased strong financial performance, highlighted by significant revenue growth and a successful acquisition that improved their leverage position. The company maintained high adjusted EBITDA and increased revenue from full risk contracts, reinforcing its profitability. However, challenges remain, primarily due to Medicaid cost trends and exposure to regulatory changes in Medicaid and health insurance exchanges. Despite these concerns, the overall sentiment is positive given the company's strong execution and strategic advancements.

Company Guidance -

Q3 2025

During the Astrana Health Second Quarter 2025 Earnings Call, the company provided updated guidance for the full year 2025, projecting total revenue between $3.1 billion and $3.3 billion and adjusted EBITDA between $215 million and $225 million. This update follows the recent acquisition of Prospect Health for $708 million, which is expected to contribute to Astrana's growth trajectory. The company reported strong financial performance for the quarter, with total revenues of $654.8 million and adjusted EBITDA of $48.1 million, signifying a 35% year-over-year revenue increase. Additionally, Astrana highlighted that 78% of its revenue now comes from full-risk contracts, and it maintained a controlled medical cost trend, slightly below the full-year expectation of 4.5%. The company also reaffirmed its medium-term adjusted EBITDA guidance of at least $350 million for 2027, demonstrating confidence in continued growth and profitability amidst industry challenges.

Strong Revenue Growth

Astrana Health reported total revenues of $654.8 million for Q2 2025, a 35% year-over-year increase, primarily driven by strong organic growth and a transition into full risk arrangements.

Successful Prospect Acquisition

Astrana Health closed the Prospect Health acquisition for $708 million, down from the initially anticipated $745 million, improving their leverage position to 2.7x net debt to pro forma adjusted EBITDA.

High Adjusted EBITDA

Adjusted EBITDA for the quarter was $48.1 million, at the higher end of guidance ranges, demonstrating disciplined growth with controlled costs.

Increased Full Risk Contract Revenue

Revenue from full risk contracts increased to 78%, up from 60% a year ago, contributing to improved profitability.

Positive Cash Flow

Astrana Health reported $20 million in free cash flow for the quarter, representing 40% of adjusted EBITDA, with expectations to achieve $90 million to $100 million for the full year.

Astrana Health (ASTH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ASTH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	0.46 / -	0.33	―	―	―
Aug 07, 2025	2025 (Q2)	0.35 / 0.19	0.4	-52.50% (-0.21)
May 08, 2025	2025 (Q1)	0.21 / 0.14	0.31	-54.84% (-0.17)
Feb 27, 2025	2024 (Q4)	0.10 / -0.15	0.26	-157.69% (-0.41)
Nov 07, 2024	2024 (Q3)	0.31 / 0.33	0.47	-29.79% (-0.14)
Aug 07, 2024	2024 (Q2)	0.39 / 0.40	0.28	42.86% (+0.12)
May 07, 2024	2024 (Q1)	0.30 / 0.31	0.31	0.00% (0.00)
Feb 27, 2024	2023 (Q4)	0.15 / 0.26	-0.06	533.33% (+0.32)
Nov 07, 2023	2023 (Q3)	0.33 / 0.47	0.56	-16.07% (-0.09)
Aug 07, 2023	2023 (Q2)	0.25 / 0.28	0.25	12.00% (+0.03)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ASTH Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$21.46	$28.08	+30.85%
May 08, 2025	$33.44	$29.71	-11.15%
Feb 27, 2025	$34.68	$25.38	-26.82%
Nov 07, 2024	$59.08	$46.96	-20.51%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Astrana Health (ASTH) report earnings?

Astrana Health (ASTH) is schdueled to report earning on Oct 30, 2025, TBA (Confirmed).

What is Astrana Health (ASTH) earnings time?

Astrana Health (ASTH) earnings time is at Oct 30, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ASTH EPS forecast?

ASTH EPS forecast for the fiscal quarter 2025 (Q3) is 0.46.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing